Stelara And Firmagon Suffer Setbacks In Draft NICE Appraisals
This article was originally published in The Pink Sheet Daily
Executive Summary
Janssen has until Jan. 17 to argue the cost-effectiveness of Stelara in the additional indication, psoriatic arthritis, while Ferring faces a restricted indication recommendation for Firmagon.
You may also be interested in...
Stelara's Triumph At NICE May Highlight Improved Focus on Drug Value
A patient access scheme from Janssen has seen Stelara through the NICE process for active psoriatic arthritis, but this doesn't mean the cost watchdog is back to focusing cost.
Janssen's Stelara Rejection At NICE Puts Innovation In The Spotlight
Janssen's Stelara has been blocked from the NHS by NICE because, although innovative, it is not the step change that the British reimbursement watchdog wants.
Ferring Firmagon’s “Positive” NICE Recommendation Still Not That Good
Severely restricted indication will see the prostate cancer drug’s revenues effectively dry up in the U.K.